Sanofi li­cens­es a pre­clin­i­cal ge­net­ic dis­ease drug from an un­known biotech spun out of the NIH

In a new deal Tues­day morn­ing, Sanofi is jump­ing in­to the an­ti­body-RNA con­ju­gate (ARC) space and el­e­vat­ing a lit­tle-known pri­vate biotech in­to the spot­light.

Sanofi is li­cens­ing a pre­clin­i­cal ARC can­di­date from Gaithers­burg, MD-based miRecule that’s de­signed to treat a ge­net­ic mus­cle dis­ease known as fa­cioscapu­lo­humer­al mus­cu­lar dy­s­tro­phy, or FSHD. Sanofi is get­ting ex­clu­sive world­wide rights for the pro­gram, known as MC-DX4, while miRecule gets an up­front and near-term mile­stones of about $30 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER